TICAGRELOR PLASMA LEVELS BUT NOT CLINICAL OUTCOMES ARE ASSOCIATED WITH TRANSPORTER AND METABOLISM ENZYME GENETIC POLYMORPHISMS

In the PLATO trial ticagrelor was superior to clopidogrel in reducing ischemic outcome and death in patients with acute coronary syndromes (ACS). Ticagrelor is a direct-acting P2Y12 receptor antagonist that is rapidly absorbed and partly metabolized to the major metabolite AR-C124910XX (ARC). ARC is